Company Description
CareDx, Inc. engages in the discovery, development, and commercialization of diagnostic solutions for transplant patients and caregivers in the United States and internationally.
It also provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients.
The company offers Olerup SSP, which is used to type human leukocyte antigen (HLA) alleles based on sequence specific primer technology; QTYPE that enables precision in HLA typing; and Ottr, a transplant patient management software.
In addition, it provides AlloSeq Tx, a high-resolution HLA typing solution; AlloSeq cfDNA, a surveillance solution to measure dd-cfDNA in blood; AlloSeq HCT, a solution for chimerism testing for stem cell transplant recipients; Allocell, a surveillance solution that monitors the level of engraftment and persistence of allogeneic cells for patients who have received cell therapy transplants; and XynQAPI cloud-based transplant quality management software, as well as AlloCare, a mobile app that offers a patient-centric resource for transplant recipients.
The company offers its products directly to customers, as well as through third-party distributors and sub-distributors.
It has a license agreement with Illumina, Inc. for the distribution, development, and commercialization of NGS products and technologies; and Cibiltech SAS to commercialize iBox, a software for the predictive analysis of post-transplantation kidney allograft loss.
The company was formerly known as XDx, Inc. and changed its name to CareDx, Inc. in March 2014. The company was incorporated in 1998 and is headquartered in South San Francisco, California.
| Country | United States |
| Founded | 1998 |
| IPO Date | Jul 17, 2014 |
| Industry | Diagnostics & Research |
| Sector | Healthcare |
| Employees | 643 |
| CEO | John Hanna |
Contact Details
Address: 8000 Marina Boulevard, Brisbane South San Francisco, California 94005 United States | |
| Phone | 415 287 2300 |
| Website | caredx.com |
Stock Details
| Ticker Symbol | CDNA |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001217234 |
| CUSIP Number | 14167L103 |
| ISIN Number | US14167L1035 |
| Employer ID | 94-3316839 |
| SIC Code | 8071 |
Key Executives
| Name | Position |
|---|---|
| John Walter Hanna Jr. | President, Chief Executive Officer and Director |
| Abhishek Jain | Chief Financial Officer and Principal Accounting Officer |
| Dr. Peter Maag Ph.D. | Executive Director |
| Keith S. Kennedy C.F.A., CPA | Chief Operating Officer |
| Dr. Robert N. Woodward Ph.D. | Chief Scientific Officer |
| Jeffrey A. Novack | General Counsel and Secretary |
| Stacey Follon | Senior Vice President and Head of Human Resources |
| Kashif Rathore | Head of Software Engineering |
| Marica Grskovic Ph.D. | Chief Strategy Officer |
| Jessica Meng | Chief Commercial Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Nov 18, 2024 | 144 | Filing |
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 8, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 5, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 4, 2024 | 10-Q | Quarterly Report |
| Nov 4, 2024 | 8-K | Current Report |
| Oct 17, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Oct 15, 2024 | 8-K | Current Report |
| Oct 8, 2024 | 8-K | Current Report |
| Oct 4, 2024 | 8-K | Current Report |